Anidulafungin is an antifungal used in the treatment of several types of candida infections. Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.
- Mechanism
- Curator reviewed
Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death.
- Primary indication
- For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis.Curator reviewed · 8 structured indications
- First approval
- Canada, 2007 · United States, 2006 · European Union, 2020
- Code names
- LY-303366 · LY-307853 · LY-329960 · LY-333006 · VEC · VER-002
- Brand names
Resolves to
What you can answer from here — as of September 23, 2026
Which drugs share a target with Anidulafungin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account